Low-Dose Oral Minoxidil Initiation for Patients With Hair Loss

作者：Yagiz Matthew Akiska, Paradi Mirmirani, Ingrid Roseborough, Erin F. Mathes, Tina Bhutani, Andrew P. Ambrosy, Crystal Aguh, Wilma F. Bergfeld, Valerie Callender, Leslie Castelo‐Soccio, George Cotsarelis, Brittany G. Craiglow, Nisha S. Desai, Isabella Doche, Bruna Duque‐Estrada, Dirk M. Elston, Carolyn Goh, Lynne J. Goldberg, Ramón Grimalt, Ali Jabbari, Victoria Jolliffe, Brett King, Charlotte LaSenna, Yolanda M. Lenzy, Jenna Lester, Nino Lortkipanidze, Kristen I. Lo Sicco, Amy McMichael, Nekma Meah, Natasha Atanaskova Mesinkovska, Mariya Miteva, Arash Mostaghimi, Yuliya Ovcharenko, Melissa Piliang, Bianca Maria Piraccini, Adriana Rakowska, Kimberly Salkey, Adriana N. Schmidt, Jerry Shapiro, Cathryn Sibbald, Rodney Sinclair, Poonkiat Suchonwanit, Susan S. Taylor, Antonellá Tosti, Sérgio Vañó-Galván, Dmitri Wall, Jennifer Fu · 发表于：JAMA Dermatology · 年份：2024 · DOI：10.1001/jamadermatol.2024.4593 · 被引用次数：30 · 研究领域：Hair Growth and Disorders、Dermatology and Skin Diseases、Neonatal skin health care

Importance: The results of small studies suggest that off-label use of low-dose oral minoxidil (LDOM) may be safe and effective for patients with hair loss, but larger trials and standardized guidelines are lacking. Objective: To create an expert consensus statement for LDOM prescribing for patients with hair loss. Evidence Review: The current literature on the pharmacological properties, adverse effect profile, and use of LDOM for patients with hair loss was reviewed. Topics of interest were identified, and a modified Delphi consensus process was created. A total of 43 hair loss specialist dermatologists from 12 countries participated in a modified Delphi process. Consensus was reached if at least 70% agreed or strongly agreed on a 5-point Likert scale. Findings: Over 4 survey rounds, 180 items in the first round, 121 items in the second round, 16 items in the third round, and 11 items in the fourth round were considered and revised. A total of 76 items achieved consensus including diagnoses for which LDOM may provide direct or supportive benefit, indications for LDOM compared to topical minoxidil, dosing for adults (18 years and older) and adolescents (aged 12 to 17 years), contraindications, precautions, baseline evaluation, monitoring, adjunctive therapy, and specialty consultation. Pediatric use and dosing items for children younger than 12 years, and LDOM titration protocols fell short of consensus. Conclusions and Relevance: This international expert consensus statemen...